[ad_1]
How safe it is and how the two vaccines give immunity to COVID-19 will be tested.
The pharmaceutical company AstraZeneca will carry out a joint study with the Russian Scientific Center “NF Gamaleya”, the Russian Fund for Direct Investment and the group “R-Pharm” in order to combine its own vaccine against coronavirus with the Russian drug “Sputnik V “. This was announced by the AstraZeneca subsidiary in Russia in a statement, quoted by AFP and TASS.
The program provides an evaluation of the safety and immunity of the combined use of the two vaccines. Volunteers over the age of 18 will participate in the research, according to the British-Swedish company.
The UK is starting vaccination against COVID-19
The French pharmaceutical corporation Sanofi and the British GSK said today that the vaccine they are developing against COVID-19 will be ready only at the end of 2021, after receiving results below those expected from the first clinical trials, reported AFP.
The course of the program “is slow to improve immune responses in the elderly,” the companies said in a general statement. They expect the drug to be available only in the last quarter of next year, although they initially expected to apply for approval in the first quarter and administer 1 billion doses that year.
Borissov: A third wave of COVID-19 and severe restrictions await us
Recently, Sanofi, which is working on the vaccine with GSK, said it plans to launch the latest human trials (the so-called phase 3) in late December, according to AFP.
Currently, the immune response in people between the ages of 18 and 49 is “comparable to that of patients recovering from COVID-19 infection,” but “insufficient” in the elderly, according to the statement.
READ ALL ABOUT CORONAVIRUS IN OUR COUNTRY AND ALL OVER THE WORLD HERE
To be the first to know the news from Bulgaria and the world, download the new NOVA app – for Android HERE or iOS (Apple) HERE.
Subscribe FREE to the nova.bg newsletter HEREto receive the most important news of the day in your email.
Source: BTA
[ad_2]
